Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	25.19B +106.3%
Revenue (ttm)	1.57B +9.0%
Net Income	568.30M +1.4%
EPS	0.10 +5.9%
Shares Out	n/a
PE Ratio	44.32
Forward PE	39.90
Dividend	0.04 (0.98%)
Ex-Dividend Date	Sep 22, 2025

Volume	n/a
Average Volume	419
Open	4.080
Previous Close	4.060
Day's Range	4.080 - 4.080
52-Week Range	2.020 - 4.800
Beta	n/a
RSI	39.40
Earnings Date	Mar 19, 2026

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 9,313
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY